Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06482437 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease
A Phase 2 study, sponsored by NMD Pharma A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
NCT06482437 is a Phase 2 study that has completed, run by NMD Pharma A/S. The registered enrollment target is 81 participants.
The verdict
NCT06482437, a Phase 2 study, has completed, sponsored by NMD Pharma A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
Study Summary
This Phase 2a study aims to evaluate the efficacy, safety and tolerability of NMD670 vs placebo administered twice a day (BID) for 21 days in ambulatory adult patients with Charcot-Marie-Tooth disease type 1 and type 2.
Interventions
- DRUG Placebo
- DRUG NMD670
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2025-11-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06482437
The ClinicalTrials.gov registry entry for NCT06482437 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NMD Pharma A/S, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06482437 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06482437 about?
NCT06482437 is a clinical study titled "Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease". This Phase 2a study aims to evaluate the efficacy, safety and tolerability of NMD670 vs placebo administered twice a day (BID) for 21 days in ambulatory adult patients with Charcot-Marie-Tooth disease type 1 and type 2.
What is the current status of trial NCT06482437?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2024-09-30. Estimated completion is 2025-11-04.
What interventions are being tested in trial NCT06482437?
The interventions under investigation include: Placebo (DRUG), NMD670 (DRUG).
Who is sponsoring clinical trial NCT06482437?
This trial is sponsored by NMD Pharma A/S, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.